Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Research groups

William McGuinness

Postdoctoral Research Scientist

My work focusses on the therapeutic avenues of enhancing lysosomal function in neurodegeneration using iPSC-derived dopaminergic neurons.

I initially joined the Wade-Martins in 2019 for my MRC-funcded iCASE DPhil in collaboration with Biogen. During this time, I studied transcriptional regulation of lysosomal biogenesis by TFEB/TFE3 in iPSC-derived dopaminergic neurons to combat lysosomal dysfunction in Parkinson's disease.

My current role is as project lead in a translational metabolomic and lipidomic biomarker study funded by the Michael J Fox Foundation in collaboration with Oxford-based biotech, EndLyz. This work aims to identify translational metabolomic and lipidomic perturbations in GBA-related Parkinson's disease, and examine how genetic and pharmacological manipulation of lysosomal channels can modify, or even correct these changes in GBA-PD. This project utilises several translational models of GBA-PD, including patient-derived iPSC-dopaminergic neurons, BAC-human transgenic mice, and post-mortem human biospecimens. This work hopes to identify key relevant biomarkers and biology highly relevant to GBA-PD, and provide a panel of biomarkers that can be used in the clinic for the use of novel pharmacological lysosomal modulators developed by EndLyz.